Sanofi Genzyme

Sanofi Genzyme, headquartered in Framingham, MA, is dedicated to advancing healthcare through its extensive portfolio focused on innovative medicines and vaccines. The company specializes in various therapeutic areas, including immunology, neurology, oncology, rare blood disorders, and rare diseases, while also emphasizing the importance of healthcare accessibility and environmental sustainability. In addition to its robust research and development initiatives, Sanofi Genzyme engages in significant scientific collaboration and offers support for healthcare professionals through managed access programs. The organization also fosters diversity, equity, and inclusion throughout its workplace and operational strategies to ensure a responsible approach to business. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

The BioExec Institute is a global non-profit organization based in Cambridge, MA, that brings together top executives, key influencers, and leading visionaries in the Life Sciences industry. Established in 2004, their primary mission is to encourage the building of important working relationships among industry leaders and promote investment and growth in the life sciences. Through their annual invitation-only retreat, The BioExec Institute provides a unique platform for approximately 80 industry figures to stay ahead of industry trends, forge direct alliances, and engage in frank and off-the-record discussions. With a focus on maximizing networking opportunities and deal-making, this organization offers an extraordinary opportunity for industry leaders to connect, exchange ideas, and address current challenges in an intimate and highly interactive setting.Generated from the website